BioNTech Targets 50 Million Vaccine Doses This Year

The transcript discusses the production and distribution of a vaccine, with plans to produce 50 million doses by the end of the year and 1.3 billion in total. It covers capacity expansion, negotiations, and distribution challenges, particularly in the UK. The effectiveness of the vaccine against mutations is addressed, along with pricing strategies during the pandemic and beyond.

How many vaccine doses are expected to be ready by the end of this year?

• 50 million

• 1.3 billion

• 10 million

• 100 million

Which company did Beyond Tech acquire a factory from to increase production capacity?

• Pfizer

• Moderna

• Novartis

• AstraZeneca

What is the expected annual production capacity of the new factory acquired by Beyond Tech?

• 500 million doses

• 1.5 billion doses

• 1 billion doses

• 750 million doses

What is the main focus of the distribution plan in the UK?

• Ensuring vaccine storage

• Developing new vaccines

• Seamless distribution to the public

• Negotiating with other countries

What is the concern regarding the N 439 K mutation?

• It is not present in Europe

• It is the most common mutation

• It does not respond to Regeneron antibodies

• It is resistant to the vaccine

What is the benchmark price per dose of the vaccine in the United States during the pandemic phase?

• $15.00

• $19.50

• $25.00

• $10.50

What is the primary goal during the pandemic phase of vaccine distribution?

• Develop new vaccines

• Vaccinate as many high-risk individuals as possible

• Maximize profits

• Negotiate with other countries